MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares

MAXCYTE, INC.

Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.
He receives $425K base salary, 45% target bonus, and a nonqualified stock option for 350K shares at $4.11/share.
Option vests over 4 years: 25% after 12 months, then monthly over 36 months.
Ron Holtz, who served as interim CFO since April 2022, becomes EVP, Administration.
Swirsky previously CFO of AavantiBio and CEO of Rexahn and GenVec; chairman of Cellectar Biosciences.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Ron Holtz

EVP, Administration

MXCT · MAXCYTE, INC.

Effective: 2023-03-27
Successor: Douglas J. Swirsky
Filed: March 28, 2023, 7:59 PM ET

Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.

Appointed

Douglas J. Swirsky

Chief Financial Officer

MXCT · MAXCYTE, INC.

Effective: 2023-03-27
Filed: March 28, 2023, 7:59 PM ET

On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ron Holtz changed role as EVP, Administration at MAXCYTE, INC..

Action: continued as
Role: EVP, Administration

Exact text from the filing

Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas J. Swirsky was appointed as Chief Financial Officer at MAXCYTE, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.

View on SEC.gov

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-037467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.